Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.14
CHE's Cash-to-Debt is ranked lower than
66% of the 257 Companies
in the Global Medical Care industry.

( Industry Median: 0.40 vs. CHE: 0.14 )
Ranked among companies with meaningful Cash-to-Debt only.
CHE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.15 Max: 1.92
Current: 0.14
0.01
1.92
Equity-to-Asset 0.60
CHE's Equity-to-Asset is ranked higher than
66% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 0.47 vs. CHE: 0.60 )
Ranked among companies with meaningful Equity-to-Asset only.
CHE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.5 Max: 0.6
Current: 0.6
0.32
0.6
Interest Coverage 48.12
CHE's Interest Coverage is ranked higher than
74% of the 216 Companies
in the Global Medical Care industry.

( Industry Median: 8.17 vs. CHE: 48.12 )
Ranked among companies with meaningful Interest Coverage only.
CHE' s Interest Coverage Range Over the Past 10 Years
Min: 8.87  Med: 11.54 Max: 50.61
Current: 48.12
8.87
50.61
Piotroski F-Score: 6
Altman Z-Score: 8.94
Beneish M-Score: -2.43
WACC vs ROIC
11.03%
18.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 11.34
CHE's Operating Margin % is ranked higher than
62% of the 255 Companies
in the Global Medical Care industry.

( Industry Median: 7.71 vs. CHE: 11.34 )
Ranked among companies with meaningful Operating Margin % only.
CHE' s Operating Margin % Range Over the Past 10 Years
Min: 9.44  Med: 11.28 Max: 11.95
Current: 11.34
9.44
11.95
Net Margin % 6.90
CHE's Net Margin % is ranked higher than
61% of the 256 Companies
in the Global Medical Care industry.

( Industry Median: 4.84 vs. CHE: 6.90 )
Ranked among companies with meaningful Net Margin % only.
CHE' s Net Margin % Range Over the Past 10 Years
Min: 5.46  Med: 6.29 Max: 7.14
Current: 6.9
5.46
7.14
ROE % 22.00
CHE's ROE % is ranked higher than
82% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 9.89 vs. CHE: 22.00 )
Ranked among companies with meaningful ROE % only.
CHE' s ROE % Range Over the Past 10 Years
Min: 16.28  Med: 19.47 Max: 22.86
Current: 22
16.28
22.86
ROA % 12.61
CHE's ROA % is ranked higher than
90% of the 259 Companies
in the Global Medical Care industry.

( Industry Median: 4.66 vs. CHE: 12.61 )
Ranked among companies with meaningful ROA % only.
CHE' s ROA % Range Over the Past 10 Years
Min: 8.17  Med: 10.25 Max: 12.88
Current: 12.61
8.17
12.88
ROC (Joel Greenblatt) % 151.52
CHE's ROC (Joel Greenblatt) % is ranked higher than
92% of the 257 Companies
in the Global Medical Care industry.

( Industry Median: 21.13 vs. CHE: 151.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CHE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 150.21  Med: 170.94 Max: 190.39
Current: 151.52
150.21
190.39
3-Year Revenue Growth Rate 7.30
CHE's 3-Year Revenue Growth Rate is ranked lower than
53% of the 183 Companies
in the Global Medical Care industry.

( Industry Median: 8.50 vs. CHE: 7.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CHE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -19.5  Med: 8.8 Max: 35
Current: 7.3
-19.5
35
3-Year EBITDA Growth Rate 11.70
CHE's 3-Year EBITDA Growth Rate is ranked higher than
60% of the 161 Companies
in the Global Medical Care industry.

( Industry Median: 8.10 vs. CHE: 11.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CHE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -35.2  Med: 8.1 Max: 78.3
Current: 11.7
-35.2
78.3
3-Year EPS without NRI Growth Rate 15.90
CHE's 3-Year EPS without NRI Growth Rate is ranked higher than
63% of the 139 Companies
in the Global Medical Care industry.

( Industry Median: 8.40 vs. CHE: 15.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CHE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -27.4  Med: 11.1 Max: 59.5
Current: 15.9
-27.4
59.5
GuruFocus has detected 5 Warning Signs with Chemed Corp $CHE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CHE's 10-Y Financials

Financials (Next Earnings Date: 2017-05-15 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CHE Guru Trades in Q1 2016

Jeremy Grantham 82,400 sh (+244.77%)
Jim Simons 148,200 sh (+72.33%)
Joel Greenblatt 86,834 sh (+1.96%)
Mario Gabelli 641,067 sh (+0.27%)
Chuck Royce 56,100 sh (unchged)
John Hussman Sold Out
Ken Fisher 549,268 sh (-0.06%)
Keeley Asset Management Corp 13,495 sh (-10.06%)
» More
Q2 2016

CHE Guru Trades in Q2 2016

Jeremy Grantham 114,877 sh (+39.41%)
Joel Greenblatt 106,927 sh (+23.14%)
Keeley Asset Management Corp 15,985 sh (+18.45%)
Mario Gabelli 644,007 sh (+0.46%)
Ken Fisher 549,908 sh (+0.12%)
Chuck Royce 56,100 sh (unchged)
Jim Simons 110,000 sh (-25.78%)
» More
Q3 2016

CHE Guru Trades in Q3 2016

Chuck Royce 56,100 sh (unchged)
Keeley Asset Management Corp 15,985 sh (unchged)
Ken Fisher 549,286 sh (-0.11%)
Mario Gabelli 635,572 sh (-1.31%)
Jim Simons 94,800 sh (-13.82%)
Joel Greenblatt 87,824 sh (-17.87%)
Jeremy Grantham 77,755 sh (-32.31%)
» More
Q4 2016

CHE Guru Trades in Q4 2016

Mario Gabelli 626,491 sh (-1.43%)
Ken Fisher 540,570 sh (-1.59%)
Keeley Asset Management Corp 15,035 sh (-5.94%)
Chuck Royce 40,888 sh (-27.12%)
Jeremy Grantham 50,712 sh (-34.78%)
Jim Simons 51,900 sh (-45.25%)
Joel Greenblatt 35,525 sh (-59.55%)
» More
» Details

Insider Trades

Latest Guru Trades with CHE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621610    SIC: 8082
Compare:OTCPK:HHCSY, OTCPK:NWKHY, NAS:LPNT, NAS:SCAI, OTCPK:LTGHY, NYSE:HLS, NAS:ACHC, NYSE:AMN, NYSE:THC, NYSE:SEM, NAS:AMED, NAS:TVTY, NYSE:CYH, NAS:LHCG, NAS:SGRY, NYSE:USPH, OTCPK:COLRY, NAS:AFAM, NAS:PRSC, OTCPK:CGMVF » details
Traded in other countries:CXM.Germany,
Headquarter Location:USA
Chemed Corp through its subsidiaries, provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers and also plumbing and drain cleaning services.

Chemed Corp was incorporated in Delaware in 1970. The company conducts its business operations in two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). VITAS Healthcare Corporation provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. Roto-Rooter provides plumbing and drain cleaning services to both residential and commercial customers. Roto-Rooter has manufacturing and distribution center facilities in West Des Moines, Iowa and has 109 leased and owned office and service facilities in 30 states. VITAS operate 51 programs from 154 leased facilities and 37 inpatient units in 18 states and the District of Columbia. The company faces competition from sewer, drain and pipe cleaning, excavation and plumbing repair businesses and is fragmented, with the bulk of the industries consisting of local and regional competitors. VITAS competes with a number of national and regional hospice providers, including Gentiva Health Services, Inc., hospitals, nursing homes, home health agencies and other health care providers. The company is subject to federal, state and local laws and regulations relating to franchising, insurance and other aspects of business.

Top Ranked Articles about Chemed Corp

Net Element Appoints New CFO for Net Elements Emerging Markets Operations

MIAMI, FL--(Marketwired - Jun 21, 2016) - Net Element, Inc. (NASDAQ: NETE) ("Net Element" or the "Company"), a provider of global mobile payment technology solutions and value-added transactional services, announced today that Roman Shakirov has been appointed the Chief Financial Officer of Net Element Russia and emerging markets. Mr. Shakirov is a highly experienced financial professional with over 13 years of experience in finance and management. He brings to the Company his extensive background in corporate finance, treasury, financial planning and analysis, tax, strategic planning and risk management. Prior to joining Net Element, Mr. Shakirov held senior positions at several leading multinational companies, including: Cherkizovo Group (LSE: CHE) (MCX: CHEP); Gallery Group; Ernst & Young and Grant Thornton. Mr. Shakirov's education includes an advanced degree from the Finance Academy under the Government of the Russian Federation with a specialization in Taxation. Mr. Shakirov led implementation of SAP ERP at Cherkizovo Group, and during his leadership, Cherkizovo Group was declared a winner of the prestigious Annual National IT Leader 2015 Prize for its outstanding contribution to the growth of the IT industry in Russia. Based in Moscow, Russia, Mr. Shakirov will work closely with the leadership teams of all Net Element Emerging Market's business units, including PayOnline and Digital Provider.  "I am pleased to welcome Roman Shakirov as CFO of Net Element Russia and emerging markets. His proven leadership skills and experience in IFRS and GAAP accounting will be a valuable resource to the company," commented Oleg Firer, CEO of Net Element. "We look forward to seeing Roman contribute to the continued growth and success of our company in CIS and selected emerging markets." "I can't imagine a more exciting time to join Net Element," commented Roman Shakirov. "Net Element is focused on powering global commerce and making a difference in digital payments in emerging markets and I am delighted to be a part of this growing company." Mr. Shakirov will lead Net Element Russia and emerging market financial operations and regional finance teams. He will report directly to Jonathan New, CFO of Net Element, Inc. About Net Element Net Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise ("SME") in the US and selected emerging markets. In the US it aims to grow transactional revenue by innovating SME productivity services such as its cloud based, restaurant point-of-sale solution Aptito. Internationally, Net Element's strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions such as UAE, Kazakhstan, Kyrgyzstan and Azerbaijan where initiatives have been recently launched. Further information is available at www.netelement.com. Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as "continue," "will," "may," "could," "should," "expect," "expected," "plans," "intend," "anticipate," "believe," "estimate," "predict," "potential," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, whether Mr. Shakirov's appointment will be beneficial to the Company, whether Net Element can secure any additional financing and if such additional financing will be adequate to meet the Company's objectives. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to: (i) Net Element's ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element's ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element's ability to successfully expand in existing markets and enter new markets; (iv) Net Element's ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element's business; (viii) changes in government licensing and regulation that may adversely affect Net Element's business; (ix) the risk that changes in consumer behavior could adversely affect Net Element's business; (x) Net Element's ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk of further U.S. government sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K and the subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.


Contact:

Net Element, Inc.

[email protected]

Phone Number: 1 786-923-0502





Read more...

Ratios

vs
industry
vs
history
PE Ratio 28.67
CHE's PE Ratio is ranked lower than
53% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. CHE: 28.67 )
Ranked among companies with meaningful PE Ratio only.
CHE' s PE Ratio Range Over the Past 10 Years
Min: 10.72  Med: 18.25 Max: 34.96
Current: 28.67
10.72
34.96
Forward PE Ratio 23.47
CHE's Forward PE Ratio is ranked lower than
73% of the 108 Companies
in the Global Medical Care industry.

( Industry Median: 18.73 vs. CHE: 23.47 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 28.67
CHE's PE Ratio without NRI is ranked lower than
51% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 28.00 vs. CHE: 28.67 )
Ranked among companies with meaningful PE Ratio without NRI only.
CHE' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.75  Med: 17.89 Max: 34.08
Current: 28.67
10.75
34.08
Price-to-Owner-Earnings 41.99
CHE's Price-to-Owner-Earnings is ranked lower than
68% of the 96 Companies
in the Global Medical Care industry.

( Industry Median: 27.48 vs. CHE: 41.99 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CHE' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.41  Med: 17.79 Max: 137.98
Current: 41.99
8.41
137.98
PB Ratio 5.75
CHE's PB Ratio is ranked lower than
83% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 2.65 vs. CHE: 5.75 )
Ranked among companies with meaningful PB Ratio only.
CHE' s PB Ratio Range Over the Past 10 Years
Min: 1.89  Med: 2.89 Max: 5.81
Current: 5.75
1.89
5.81
PS Ratio 2.00
CHE's PS Ratio is ranked lower than
57% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. CHE: 2.00 )
Ranked among companies with meaningful PS Ratio only.
CHE' s PS Ratio Range Over the Past 10 Years
Min: 0.67  Med: 1.05 Max: 2.02
Current: 2
0.67
2.02
Price-to-Free-Cash-Flow 32.48
CHE's Price-to-Free-Cash-Flow is ranked lower than
61% of the 106 Companies
in the Global Medical Care industry.

( Industry Median: 23.72 vs. CHE: 32.48 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CHE' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.31  Med: 14.2 Max: 81.99
Current: 32.48
7.31
81.99
Price-to-Operating-Cash-Flow 23.03
CHE's Price-to-Operating-Cash-Flow is ranked lower than
72% of the 154 Companies
in the Global Medical Care industry.

( Industry Median: 14.15 vs. CHE: 23.03 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CHE' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.07  Med: 10.77 Max: 29.92
Current: 23.03
6.07
29.92
EV-to-EBIT 16.85
CHE's EV-to-EBIT is ranked higher than
55% of the 292 Companies
in the Global Medical Care industry.

( Industry Median: 18.39 vs. CHE: 16.85 )
Ranked among companies with meaningful EV-to-EBIT only.
CHE' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.1  Med: 10.7 Max: 18.8
Current: 16.85
7.1
18.8
EV-to-EBITDA 14.14
CHE's EV-to-EBITDA is ranked lower than
54% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 13.46 vs. CHE: 14.14 )
Ranked among companies with meaningful EV-to-EBITDA only.
CHE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.8  Med: 8.8 Max: 15.3
Current: 14.14
5.8
15.3
PEG Ratio 3.39
CHE's PEG Ratio is ranked lower than
56% of the 94 Companies
in the Global Medical Care industry.

( Industry Median: 3.11 vs. CHE: 3.39 )
Ranked among companies with meaningful PEG Ratio only.
CHE' s PEG Ratio Range Over the Past 10 Years
Min: 0.2  Med: 1.28 Max: 3.43
Current: 3.39
0.2
3.43
Shiller PE Ratio 40.17
CHE's Shiller PE Ratio is ranked lower than
62% of the 45 Companies
in the Global Medical Care industry.

( Industry Median: 28.31 vs. CHE: 40.17 )
Ranked among companies with meaningful Shiller PE Ratio only.
CHE' s Shiller PE Ratio Range Over the Past 10 Years
Min: 22.86  Med: 34.3 Max: 76.53
Current: 40.17
22.86
76.53
Current Ratio 0.99
CHE's Current Ratio is ranked lower than
66% of the 244 Companies
in the Global Medical Care industry.

( Industry Median: 1.30 vs. CHE: 0.99 )
Ranked among companies with meaningful Current Ratio only.
CHE' s Current Ratio Range Over the Past 10 Years
Min: 0.62  Med: 1.27 Max: 1.93
Current: 0.99
0.62
1.93
Quick Ratio 0.96
CHE's Quick Ratio is ranked lower than
63% of the 244 Companies
in the Global Medical Care industry.

( Industry Median: 1.18 vs. CHE: 0.96 )
Ranked among companies with meaningful Quick Ratio only.
CHE' s Quick Ratio Range Over the Past 10 Years
Min: 0.6  Med: 1.07 Max: 1.79
Current: 0.96
0.6
1.79
Days Inventory 1.99
CHE's Days Inventory is ranked higher than
90% of the 192 Companies
in the Global Medical Care industry.

( Industry Median: 16.88 vs. CHE: 1.99 )
Ranked among companies with meaningful Days Inventory only.
CHE' s Days Inventory Range Over the Past 10 Years
Min: 1.97  Med: 2.93 Max: 3.3
Current: 1.99
1.97
3.3
Days Sales Outstanding 30.56
CHE's Days Sales Outstanding is ranked higher than
66% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 40.40 vs. CHE: 30.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
CHE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 16.39  Med: 27.85 Max: 34.21
Current: 30.56
16.39
34.21
Days Payable 12.95
CHE's Days Payable is ranked lower than
83% of the 162 Companies
in the Global Medical Care industry.

( Industry Median: 40.41 vs. CHE: 12.95 )
Ranked among companies with meaningful Days Payable only.
CHE' s Days Payable Range Over the Past 10 Years
Min: 12.95  Med: 17.63 Max: 23.78
Current: 12.95
12.95
23.78

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.56
CHE's Dividend Yield % is ranked lower than
88% of the 247 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. CHE: 0.56 )
Ranked among companies with meaningful Dividend Yield % only.
CHE' s Dividend Yield % Range Over the Past 10 Years
Min: 0.35  Med: 0.73 Max: 1.2
Current: 0.56
0.35
1.2
Dividend Payout Ratio 0.15
CHE's Dividend Payout Ratio is ranked higher than
95% of the 146 Companies
in the Global Medical Care industry.

( Industry Median: 0.41 vs. CHE: 0.15 )
Ranked among companies with meaningful Dividend Payout Ratio only.
CHE' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.08  Med: 0.15 Max: 0.18
Current: 0.15
0.08
0.18
3-Year Dividend Growth Rate 9.60
CHE's 3-Year Dividend Growth Rate is ranked lower than
56% of the 82 Companies
in the Global Medical Care industry.

( Industry Median: 11.70 vs. CHE: 9.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
CHE' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -42.4  Med: 2.2 Max: 35.7
Current: 9.6
-42.4
35.7
Forward Dividend Yield % 0.56
CHE's Forward Dividend Yield % is ranked lower than
92% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 1.84 vs. CHE: 0.56 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.91
CHE's 5-Year Yield-on-Cost % is ranked lower than
83% of the 311 Companies
in the Global Medical Care industry.

( Industry Median: 2.23 vs. CHE: 0.91 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
CHE' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.58  Med: 1.21 Max: 1.99
Current: 0.91
0.58
1.99
3-Year Average Share Buyback Ratio 2.60
CHE's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 130 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. CHE: 2.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CHE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -9.8  Med: 1.4 Max: 6.4
Current: 2.6
-9.8
6.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.79
CHE's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
56% of the 89 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. CHE: 1.79 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CHE' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.63  Med: 1.24 Max: 2.05
Current: 1.79
0.63
2.05
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.77
CHE's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
56% of the 32 Companies
in the Global Medical Care industry.

( Industry Median: 1.81 vs. CHE: 1.77 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.89
CHE's Price-to-Median-PS-Value is ranked lower than
86% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 1.04 vs. CHE: 1.89 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CHE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.3  Med: 0.85 Max: 1.91
Current: 1.89
0.3
1.91
Price-to-Peter-Lynch-Fair-Value 3.43
CHE's Price-to-Peter-Lynch-Fair-Value is ranked lower than
77% of the 47 Companies
in the Global Medical Care industry.

( Industry Median: 2.13 vs. CHE: 3.43 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CHE' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.55  Med: 1.39 Max: 3.46
Current: 3.43
0.55
3.46
Earnings Yield (Greenblatt) % 5.94
CHE's Earnings Yield (Greenblatt) % is ranked higher than
62% of the 334 Companies
in the Global Medical Care industry.

( Industry Median: 4.98 vs. CHE: 5.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CHE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 5.3  Med: 9.4 Max: 14.2
Current: 5.94
5.3
14.2
Forward Rate of Return (Yacktman) % 11.57
CHE's Forward Rate of Return (Yacktman) % is ranked higher than
52% of the 119 Companies
in the Global Medical Care industry.

( Industry Median: 11.19 vs. CHE: 11.57 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CHE' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 11.57  Med: 19 Max: 72.8
Current: 11.57
11.57
72.8

More Statistics

Revenue (TTM) (Mil) $1,577
EPS (TTM) $ 6.49
Beta1.52
Short Percentage of Float13.90%
52-Week Range $124.78 - 190.32
Shares Outstanding (Mil)16.08

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 1,632 1,706
EPS ($) 7.92 8.47
EPS without NRI ($) 7.92 8.47
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.00%
Dividends per Share ($)
» More Articles for CHE

Headlines

Articles On GuruFocus.com
Net Element Appoints New CFO for Net Elements Emerging Markets Operations Jun 21 2016 
John Hussman Sells Broadcom, Cognizant May 13 2016 
Mario Gabelli Comments on Chemed Corp. Jan 29 2014 
The Gabelli Asset Fund Shareholder Commentary - Fourth Quarter 2013 Jan 29 2014 
3 Cheap Health Care Dividend Stocks with Huge Potential to Grow Dividends Oct 02 2013 
Chemed Corporation: Fundamental Stock Research Analysis Jan 29 2013 
12 Healthcare Dividend Stocks With Highest Short Float Ratio Jun 02 2012 
9 Dividend Stocks Raising Their Yield On Cost Aug 15 2011 
Guru Stocks Raising Dividends: THO, ACU, KAMN, PRIM, CHE Aug 15 2011 
Chemed Corp. Reports Operating Results (10-K) Feb 28 2011 

More From Other Websites
Chemed To Report First-Quarter 2017 Earnings April 26, Related Conference Call To Be Held On April... Apr 06 2017
5 Cheap Value Stocks to Tame a Capricious Market in Q2 Apr 04 2017
Chemed (CHE) Up 6.4% Since Earnings Report: Can It Continue? Mar 21 2017
Chemed Corporation to Present at the Oppenheimer 27th Annual Healthcare Conference Mar 15 2017
Chemed Corporation’s Board of Directors Authorizes an Additional $100 Million for Stock Repurchase Mar 13 2017
5 Stocks to Buy for the Post-Obamacare Era Feb 27 2017
Chemed Corp. :CHE-US: Earnings Analysis: 2016 By the Numbers : February 22, 2017 Feb 22 2017
Chemed Corporation Declares Quarterly Dividend of 26 Cents Feb 17 2017
Chemed Corp. :CHE-US: Earnings Analysis: Q4, 2016 By the Numbers : February 17, 2017 Feb 17 2017
Chemed Corporation to Present at the 2017 RBC Capital Markets’ Global Healthcare Conference Feb 16 2017
Chemed (CHE) Misses Q4 Earnings, Sales; Offers '17 View Feb 16 2017
Chemed posts 4Q profit Feb 15 2017
Chemed Reports Fourth-Quarter 2016 Results Feb 15 2017
Chemed To Report Fourth-Quarter 2016 Earnings February 15, Related Conference Call To Be Held On... Jan 20 2017
ETFs with exposure to Chemed Corp. : December 21, 2016 Dec 21 2016
Chemed (CHE): Roto-Rooter Solid, Reimbursement a Concern Dec 21 2016
Do Hedge Funds Love Sterling Bancorp (STL)? Dec 08 2016
Is Chemed Corporation (CHE) Going to Burn These Hedge Funds? Dec 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)